危重症患者哌拉西林与他唑巴坦血浆及尿液整合群体药代动力学分析
本研究纳入39例接受哌拉西林-他唑巴坦治疗的成人ICU患者,采用非线性混合效应模型整合分析血浆及尿液药物浓度,建立联合二室线性药代动力学模型。蒙特卡洛模拟显示12/1.5 g/24 h持续输注可使多数患者他唑巴坦及哌拉西林达标,但MIC 16 mg/L时治疗窗狭窄,且19.6%与47.8%患者分别在接受12 g/24 h与20 g/24 h哌拉西林时出现潜在毒性浓度。
要点
- 12/1.5 g/24 h持续输注可使>90%危重症患者覆盖MIC≤8 mg/L的大肠埃希菌和肺炎克雷伯菌。
- MIC 16 mg/L铜绿假单胞菌感染时,哌拉西林治疗窗狭窄,20 g/24 h亦不足以达100% fT>5×MIC。
- 12 g/24 h与20 g/24 h哌拉西林分别有19.6%和47.8%患者达潜在毒性浓度,建议结合肾功能与TDM调整剂量。
核心结论
- 整合血浆与尿液群体药代动力学模型可同时描述哌拉西林和他唑巴坦的暴露,并支持危重症患者 dosing 评估。
- 常规剂量12/1.5 g/24 h在>90%危重症人群中足以治疗MIC≤8 mg/L的大肠埃希菌和肺炎克雷伯菌感染。
- MIC 16 mg/L铜绿假单胞菌感染时治疗暴露与毒性暴露界限狭窄,需肾功能指导及TDM优化给药。
研究设计与样本
- 观察性研究,纳入39例接受哌拉西林-他唑巴坦常规治疗的成人ICU患者。
- 测定血浆及尿液中哌拉西林和他唑巴坦浓度,采用非线性混合效应模型进行整合群体药代动力学分析。
- 通过蒙特卡洛模拟预测不同给药策略及不同肾功能分类下的药物浓度。
主要发现
- 建立了哌拉西林和他唑巴坦联合二室线性药代动力学模型,并包含经肾排泄的输出隔室。
- 加入24小时尿肌酐清除率显著改善模型拟合。
- 12/1.5 g/24 h持续输注可达他唑巴坦目标浓度2.89 mg/L以上及哌拉西林100% fT>1×MIC(MIC≤16 mg/L)。
- MIC 16 mg/L时,哌拉西林剂量高达20 g/24 h仍不足以达到100% fT>5×MIC目标。
- 哌拉西林12 g/24 h和20 g/24 h分别有19.6%和47.8%患者达到潜在毒性浓度。
关键数值与推荐
- 他唑巴坦目标浓度2.89 mg/L。
- 哌拉西林目标为100% fT>1×MIC(MIC≤16 mg/L)或100% fT>5×MIC(MIC 16 mg/L)。
- 12/1.5 g/24 h持续输注在>90%危重症人群中足以治疗MIC≤8 mg/L的大肠埃希菌和肺炎克雷伯菌感染。
- 哌拉西林12 g/24 h与20 g/24 h的潜在毒性浓度发生率分别为19.6%和47.8%。
临床怎么用
- 对MIC≤8 mg/L的大肠埃希菌和肺炎克雷伯菌感染,可考虑12/1.5 g/24 h持续输注。
- 对MIC 16 mg/L铜绿假单胞菌感染,应结合肾功能评估并开展TDM以平衡疗效与毒性。
- 使用较高剂量哌拉西林(如12 g/24 h或20 g/24 h)时需警惕潜在毒性暴露,尤其在高暴露风险患者中。
局限性
- 样本量较小(39例成人ICU患者),可能限制结果的普遍性。
- 研究为观察性设计,模拟结果需在前瞻性临床研究中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Although dose optimization studies have been performed for piperacillin and tazobactam separately, a combined integral analysis is not yet reported. As piperacillin and tazobactam pharmacokinetics are likely to show correlation, a combined pharmacokinetic model should be preferred to account for this correlation when predicting the exposure. Therefore, the aim of this study was to describe the pharmacokinetics and evaluate different dosing regimens of piperacillin and tazobactam in critically ill patients using an integral population pharmacokinetic model in plasma and urine. METHODS: In this observational study, a total of 39 adult intensive care unit patients receiving piperacillin-tazobactam as part of routine clinical care were included. Piperacillin and tazobactam concentrations in plasma and urine were measured and analyzed using non-linear mixed-effects modeling. Monte Carlo simulations were performed to predict the concentrations for different dosing strategies and different categories of renal function. RESULTS: A combined two-compartment linear pharmacokinetic model for both piperacillin and tazobactam was developed, with an output compartment for the renally excreted fraction. The addition of 24-h urine creatinine clearance significantly improved the model fit. A dose of 12/1.5 g/24 h as a continuous infusion is sufficient to reach a tazobactam concentration above the target (2.89 mg/L) and a piperacillin concentration above the target of 100% f T>1×MIC (minimum inhibitory concentration [MIC] ≤ 16 mg/L). To reach a target of 100% f T>5×MIC with an MIC of 16 mg/L, piperacillin doses of up to 20 g/24 h are inadequate. Potential toxic piperacillin levels were reached in 19.6% and 47.8% of the population with a dose of 12 g/24 h and 20 g/24 h, respectively. CONCLUSIONS: A regular dose of 12/1.5 g/24 h is sufficient in > 90% of the critically ill population to treat infections caused by Escherichia coli and Klebsiella pneumoniae with MICs ≤ 8 mg/L. In case of infections caused by Pseudomonas aeruginosa with an MIC of 16 mg/L, there is a fine line between therapeutic and toxic exposure. Dosing guided by renal function and therapeutic drug monitoring could enhance target attainment in such cases. GOV IDENTIFIER: NCT03738683.
引用
- Wallenburg E, Ter Heine R, Schouten JA, et al. An Integral Pharmacokinetic Analysis of Piperacillin and Tazobactam in Plasma and Urine in Critically Ill Patients. Clin Pharmacokinet. 2022. PMID: 35377133. doi:10.1007/s40262-022-01113-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。